Michelle Mitchell: C-Further’s Second Annual Review on Childhood Cancer Drug Development
Michelle Mitchell/cancerresearchuk.org

Michelle Mitchell: C-Further’s Second Annual Review on Childhood Cancer Drug Development

Michelle Mitchell, Chief Executive at Cancer Research UK, shared on LinkedIn:

“We will not transform outcomes for children and young people with cancer by doing more of the same.

The reality is that the system for developing new medicines does not work quickly enough or effectively enough for many children with cancer. If we want faster progress, we need new models, new partnerships and greater collaboration across the research ecosystem.

That’s why Cancer Research UK (CRUK), LifeArc and Great Ormond Street Hospital Charity established C-Further: a global collaborative effort focused on accelerating the development of medicines specifically for children and young people with cancer.

The publication of C-Further’s second annual review marks another important step forward. It’s encouraging to see the first projects now moving ahead, bringing together expertise from researchers, industry and patient advocates around the world. Even more importantly, people with lived experience are helping shape the programme and its priorities.

No single organisation can solve these challenges alone. But by combining expertise, investment, innovation and lived experience, we can create a stronger pathway to new treatments for children and young people who urgently need them. There is much more to do, but this is exactly the kind of ambitious collaboration that gives me hope for the future.

Thank you to James Pickett, Iain Foulkes, Tony Hickson and all those helping drive this important work forward.”

You can also read:

PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers: MiNK Therapeutics and C-Further Partner to Advance Development

Michelle Mitchell: C-Further’s Second Annual Review on Childhood Cancer Drug Development